Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1802 plus SHR-1316 in advanced solid tumors (phase Ib/II, open-label, multicenter)
CTR20230854Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1802 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started May 2023; status: active.
02
Drugs
SHR-1802
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230854.